替加环素临床耐药性的研究进展

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (4): 466-468.

替加环素临床耐药性的研究进展

罗丹¹, 郝刚², 林思思¹, 郭文靖¹, 夏宇轩¹, 吕良忠¹

¹浙江省人民医院药学部,杭州 310014,浙江;
²苏州市食品药品检验所,苏州 215104,江苏

收稿日期:2013-11-30 修回日期:2014-07-07 发布日期:2015-05-07
通讯作者: 吕良忠,男,博士,硕士生导师,研究方向:临床药学。Tel: 0571-85893889 E-mail: vliangzhong@126.com
作者简介:罗丹,女,硕士,研究方向:临床药学。Tel: 0571-85893889 E-mail: luodan1230@163.com

Research progress on the clinical resistance to tigecycline

LUO Dan¹, HAO Gang², LIN Si-si¹, GUO Wen-jing¹, XIA Yu-xuan¹, LV Liang-zhong¹

¹ Department of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou 310014, Zhejiang,China;
² Suzhou Institute for Food and Drug Control, Suzhou 215104, Jiangsu,China

Received:2013-11-30 Revised:2014-07-07 Published:2015-05-07

摘要/Abstract

摘要： 替加环素作为新一代四环素类抗生素,被用于治疗成人复杂性腹腔内感染和复杂性皮肤及软组织感染。随着临床的广泛使用,替加环素耐药性也屡见报道,或影响其临床疗效。本文对替加环素临床耐药性的研究进展,包括药理作用、临床应用、耐药性的发展以及可能的耐药机制进行综述。

关键词: 替加环素, 耐药性, 耐药机制

Abstract: As a new glycylcycline antimicrobial agent, tigecycline (TIG) has been proved an effective therapeutic agent for the treatment of adult complicated intra-abdominal infections and complicated skin and skin structure infections. However, increasing evidence of drug resistance has been reported following the clinical treatment with TIG. This article offers an update overview of TIG pharmacological investigations, clinical applications, current microbial resistance and relative mechanisms.

Key words: tigecycline, drug resistance, resistance mechanism

中图分类号:

R978.1⁺4

罗丹, 郝刚, 林思思, 郭文靖, 夏宇轩, 吕良忠. 替加环素临床耐药性的研究进展[J]. 中国临床药理学与治疗学, 2015, 20(4): 466-468.

LUO Dan, HAO Gang, LIN Si-si, GUO Wen-jing, XIA Yu-xuan, LV Liang-zhong. Research progress on the clinical resistance to tigecycline[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 466-468.

参考文献

[1] Brink AJ, Bizos D, Boffard KD, et al. Guideline: appropriate use of tigecycline[J]. S Afr Med J,2010,100 (6 Pt 2):388-394.
[2] Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: A comparative review with the tetracyclines[J]. Drugs,2004,64(1):63-88.
[3] Guay DR. Oritavancin and tigecycline: Investigational antimicrobials for multidrug-resistant bacteria[J]. Pharmacotherapy,2004,24(1):58-68.
[4] Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline[J]. Expert Opin Drug Metab Toxicol,2011,7(11):1459-1470.
[5] Bassetti M, Eckmann C, Bodmann KF, et al. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies[J]. J Antimicrob Chemother,2013,68:5-14.
[6] Sun Y, Cai Y, Liu X, et al. The emergence of clinical resistance to tigecycline[J]. Int J Antimicrob Agents,2013,41(2):110-116.
[7] Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease[J]. Antimicrob Agents Chemother,2011,55(3):1162-1172.
[8] Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-analysis[J]. Lancet Infect Dis,2011,11(11):834-844.
[9] Verkade EJ, Verhulst CJ, Huijsdens XW, et al. In vitro activity of tigecycline against methicillin-resistant staphylococcus aureus, including livestock-associated strains[J]. Eur J Clin Microbiol Infect Dis,2010,29(5):503-507.
[10]Garza-Gonzalez E, Llaca-Diaz JM, Bosques-Padilla FJ, et al. Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in mexico: Special focus on acinetobacter baumannii[J]. Chemotherapy,2010,56(4):275-279.
[11]Tubau F, Linares J, Rodriguez MD, et al. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery[J]. Diagn Microbiol Infect Dis,2010,66(3):308-313.
[12]Darabi A, Hocquet D, Dowzicky MJ. Antimicrobial activity against streptococcus pneumoniae and haemophilus influenzae collected globally between,2004 and 2008 as part of the tigecycline evaluation and surveillance trial[J]. Diagn Microbiol Infect Dis,2010,67(1):78-86.
[13]李小宁, 李娟, 姚永红. 鲍曼不动杆菌的耐药性及产ESBL和碳青霉烯酶分析[J]. 中国临床药理学与治疗学, 2012, 17(1): 30-31.
[14]Chang KC, Lin MF, Lin NT, et al. Clonal spread of multidrug-resistant acinetobacter baumannii in eastern taiwan[J]. J Microbiol Immunol Infect,2012,45(1):37-42.
[15]Taneja N, Singh G, Singh M, et al. Emergence of tigecycline & colistin resistant acinetobacter baumanii in patients with complicated urinary tract infections in north india[J]. Indian J Med Res,2011,133:681-684.
[16]Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in acinetobacter species isolated from patients in kuwait hospitals[J]. J Chemother,2011,23(1):13-16.
[17]Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant acinetobacter baumannii[J]. J Antimicrob Chemother,2007,59(1):772-774.
[18]Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline[J]. Int J Antimicrob Agents,2011,37(5):415-419.
[19]Zhang R, Sun Q, Hu YJ, et al. Detection of the smqnr quinolone protection gene and its prevalence in clinical isolates of stenotrophomonas maltophilia in china[J]. J Med Microbiol,2012,61(4):535-539.
[20]Linkevicius M, Sandegren L, Andersson DI. Mechanisms and fitness costs of tigecycline resistance in escherichia coli[J]. J Antimicrob Chemother,2013,68(12):2809-2019.[21]Keeney D, Ruzin A, McAleese F, et al. Mara-mediated overexpression of the acrab efflux pump results in decreased susceptibility to tigecycline in escherichia coli[J]. J Antimicrob Chemother,2008,61(1):46-53.
[22]Horiyama T, Nikaido E, Yamaguchi A, et al. Roles of salmonella multidrug efflux pumps in tigecycline resistance[J]. J Antimicrob Chemother,2011,66(1):105-110.
[23]Volkers G, Palm GJ, Weiss MS, et al. Structural basis for a new tetracycline resistance mechanism relying on the tetx monooxygenase[J]. FEBS Lett,2011,585(7):1061-1066.